Sign in
Combining the HSP90 inhibitor TAS-116 with metformin effectively degrades the NLRP3 and attenuates inflammasome activation in rats: A new management paradigm for ulcerative colitis
Journal article   Peer reviewed

Combining the HSP90 inhibitor TAS-116 with metformin effectively degrades the NLRP3 and attenuates inflammasome activation in rats: A new management paradigm for ulcerative colitis

Ahmed A. Shaaban, Amir Mohamed Abdelhamid, Mohamed E. Shaker, Simona Cavalu, Adrian Marius Maghiar, Abdulrahman A. Alsayegh, Ahmad O. Babalghith, Eman El-Ahwany, Noha A. Amin, Osama A. Mohammed, …
Biomedicine & pharmacotherapy, Vol.153, pp.113247-113247
09/2022
PMID: 35724510

Abstract

Colitis HSP90 inhibitor Inflammasome NLRP3 autophagic degradation TAS-116/metformin

Metrics

1 Record Views

Details